Is SRPT's Q4 2024 earnings growth sustainable?

Sarepta Therapeutics (SRPT) faces challenges in sustaining its Q4 2024 earnings growth due to:

1. **Recent Setback with Elevidys**: The death of a patient from acute liver failure following treatment with Sarepta's gene therapy, ELEVIDYS, has led to safety concerns and a subsequent pause in trials in the EU. This incident may impact market confidence and future sales.
2. **Investigations and Legal Challenges**: Sarepta is under investigation for potential securities fraud, adding uncertainty to its financial outlook. Investor confidence may be affected, leading to potential declines in stock price and revenue.

In conclusion, while Sarepta Therapeutics has shown strong earnings growth in Q4 2024, the sustainability of this growth is currently threatened by safety concerns and legal investigations. These factors could lead to a decline in investor confidence and ultimately affect the company's financial performance.